Greater Gut Bacterial Diversity Evident With Kalydeco’s Use

Greater Gut Bacterial Diversity Evident With Kalydeco’s Use

296318

Greater Gut Bacterial Diversity Evident With Kalydeco’s Use

Two months of treatment with Kalydeco (ivacaftor) by cystic fibrosis (CF) patients who carry a CFTR gating mutation significantly increased the diversity of bacteria in the gut but not in the respiratory system, a small study reported. A larger and longer study might be necessary to best determine how treatment affects the respiratory system, its researchers wrote, as previous work “suggest[s] that development of respiratory tract microbiota is presaged by gut colonization patterns and nutritional factors.” The…

You must be logged in to read/download the full post.